デフォルト表紙
市場調査レポート
商品コード
1429379

新型コロナウイルス感染症(COVID-19)の最新治療の世界市場レポート 2024年

COVID-19 Current Therapy Global Market Report 2024

出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 250 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.11円
新型コロナウイルス感染症(COVID-19)の最新治療の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 250 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 目次
概要

新型コロナウイルス感染症(COVID-19)の最新治療の市場規模は、今後数年間で急激に減少すると予想されています。 2025年には、年間複合成長率(CAGR)-60.1%で23億4,000万米ドルまで減少すると予想されます。予測期間の減少は、世界のワクチン展開の影響、長期的な影響と慢性症例、規制と市場アクセスの課題、世界の経済要因に起因すると考えられます。予測期間の主要動向には、モノクローナル抗体療法、回復期血漿療法、細胞ベースの療法、抗ウイルス療法の開発への投資、政府機関との協力、他の製薬会社との戦略的提携が含まれます。

新型コロナウイルス感染症(COVID-19)のパンデミックの発生は、新型コロナウイルス感染症(COVID-19)の最新治療市場の成長に大きく貢献しました。世界保健機関(WHO)はこの発生を世界のパンデミックと宣言し、2022年8月の時点で報告された世界のCOVID-19感染症感染者数は5億8,180万人に達しました。新型コロナウイルス感染症(COVID-19)に対して正式に承認された薬剤がないため、コロナ治療に使用される再利用薬剤に対する大きな需要があります。世界中の国々が医薬品不足に悩まされており、メーカーは世界の需要の急増に対応するために生産を拡大するよう求められています。 FDAによって開始されたCOVID-19感染症治療加速プログラム(CTAP)は、潜在的な新型COVID-19治療薬の開発を促進し、患者に迅速に提供できるように設計された特別な緊急プログラムです。

新型コロナウイルス感染症(COVID-19)の最新治療市場の予想される成長は、医療インフラの拡大によっても推進されています。医療業界は、患者の治癒、予防、リハビリテーション、緩和ケアを提供する製品とサービスを提供する部門を統合する上で重要な役割を果たしています。堅牢な医療インフラは、COVID-19治療を効果的に実施し、タイムリーな患者ケアを確保し、調査や臨床試験をサポートし、最適な治療を提供するために不可欠なリソースを提供するために不可欠です。実例として、2023年 5月に米国医療協会は、米国の病院数が2022年の6,093から6,129に増加したと報告しました。さらに、英国国家統計局の報告書では、2020年から2021年にかけて英国の医療支出が名目で9.4%増加し、実質で9.7%増加したことが明らかになりました。したがって、医療業界の拡大は、新型コロナウイルス感染症(COVID-19)の最新治療市場の成長を推進する主要な推進力です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の新型コロナウイルス感染症(COVID-19)の最新治療市場の促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の新型コロナウイルス感染症(COVID-19)の最新治療市場規模実績と成長率、2020年から2023年
  • 世界の新型コロナウイルス感染症(COVID-19)の最新治療市場規模と成長予測、2023~2024年、2025年

第6章 市場セグメンテーション

  • 世界の新型コロナウイルス感染症(COVID-19)の最新治療市場、薬剤タイプ別セグメンテーション、実績と予測、2020~2023年、2023~2024年、2025年
  • レムデシビル
  • ヒドロキシクロロキン
  • リトナビル
  • ロピナビル
  • インターフェロンベータ
  • その他
  • 世界の新型コロナウイルス感染症(COVID-19)の最新治療市場、投与経路別セグメンテーション、実績と予測、2020~2023年、2023~2024年、2025年
  • 経口
  • 静脈内
  • 世界の新型コロナウイルス感染症(COVID-19)の最新治療市場、エンドユーザー別セグメンテーション、実績と予測、2020~2023年、2023~2024年、2025年
  • 病院
  • クリニック
  • 研究機関
  • その他

第7章 地域と国の分析

  • 世界の新型コロナウイルス感染症(COVID-19)の最新治療市場、地域別、実績と予測、2020~2023年、2023~2024年、2025年
  • 世界の新型コロナウイルス感染症(COVID-19)の最新治療市場、国別、実績と予測、2020~2023年、2023~2024年、2025年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 新型コロナウイルス感染症(COVID-19)の最新治療市場の競合情勢
  • 新型コロナウイルス感染症(COVID-19)の最新治療市場の企業プロファイル
    • Gilead Sciences, Inc.
    • F. Hoffmann-La Roche AG
    • Ipca Laboratories Limited
    • Zydus Cadila
    • Regeneron Pharmaceuticals, Inc.

第31章 その他の大手と革新的な企業

  • Sun Pharmaceutical Industries Limited
  • AbbVie
  • Glenmark Pharmaceuticals Limited
  • Eli Lilly and Company
  • Wallace Pharmaceuticals, Inc.
  • Mylab Discovery Solutions
  • Kalbe Farma
  • He Qi Group Foundation
  • Beijing Jinwofu Bioengineering Technology Company
  • Zhejiang Orient Gene Biotech Co. Ltd
  • Transasia Bio Medicals
  • Vanguard Diagnostics
  • HLL Lifecare Limited
  • Voxtur Bio Ltd
  • Biocryst Pharma

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の展望と潜在性分析

第36章 付録

目次
Product Code: r14391

The current therapy for COVID-19 pertains to drugs formulated and utilized for treating mild to moderate cases in individuals at higher risk of severe illness from the virus.

Key drug categories in COVID-19 therapy comprise antivirals, monoclonal antibodies, corticosteroids, supplements, antimalarials, interferons, interleukin inhibitors, other anti-infective medications, and similar treatments. Antivirals are specific medications or compounds crafted to impede virus growth and replication, targeting various stages of the viral life cycle or disrupting viral processes. These drugs are administered via oral or intravenous routes and find application across hospitals, clinics, research institutes, and related sectors.

The COVID-19 current therapy market research report is one of a series of new reports from The Business Research Company that provides COVID-19 current therapy market statistics, including COVID-19 current therapy industry global market size, regional shares, competitors with a COVID-19 current therapy market share, detailed COVID-19 current therapy market segments, COVID-19 current therapy market trends and opportunities, and any further data you may need to thrive in the COVID-19 current therapy industry. This COVID-19 current therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The COVID-19 current therapy market size has declined steeply in recent years. It will decline from $11.73 billion in 2023 to $5.87 billion in 2024 at a compound annual growth rate (CAGR) of -50.0%. The decline in the historic period can be attributed to limited treatment options, varying treatment efficacy, supply chain disruptions, rapidly evolving scientific knowledge, emergence of variants.

The COVID-19 current therapy market size is expected to see steep decline in the next few years. It will decline to $2.34 billion in 2025 at a compound annual growth rate (CAGR) of -60.1%. The decline in the forecast period can be attributed to global vaccine rollout impact, long-term effects and chronic cases, regulatory and market access challenges, global economic factors. Major trends in the forecast period include investing in developing monoclonal antibody therapies, convalescent plasma therapies, cell-based therapies, and antiviral therapies, collaboration with government institutions and undergoing strategic partnerships with other pharmaceutical companies.

The outbreak of the COVID-19 pandemic has significantly contributed to the growth of the COVID-19 current therapy market. The World Health Organization (WHO) declared the outbreak a global pandemic, and as of August 2022, reported global COVID-19 cases had reached 581.8 million. With no officially approved drug for COVID-19, there has been a substantial demand for repurposed drugs used in corona therapy. Countries worldwide are grappling with drug shortages, prompting manufacturers to scale up production to meet the surging global demand. The COVID-19 Treatment Acceleration Program (CTAP), initiated by the FDA, is a special emergency program designed to expedite the development of potential COVID-19 therapies for swift availability to patients.

The anticipated growth of the COVID-19 current therapy market is also driven by the expansion of healthcare infrastructure. The healthcare industry plays a crucial role in integrating sectors that provide products and services for curing, preventing, rehabilitating, and offering palliative care to patients. A robust healthcare infrastructure is essential for the effective implementation of COVID-19 therapies, ensuring timely patient care, supporting research and clinical trials, and providing essential resources for optimal treatment delivery. As an illustration, in May 2023, the American Health Care Association reported an increase in the number of hospitals in the US from 6,093 in 2022 to 6,129. Additionally, a report by the UK's Office for National Statistics revealed a 9.4% increase in healthcare spending in the UK between 2020 and 2021 in nominal terms, and a 9.7% increase in real terms. Hence, the expansion of the healthcare industry is a key driver propelling the growth of the COVID-19 current therapy market.

Convalescent Plasma Therapy has emerged as an experimental treatment for COVID-19 patients, involving the use of blood plasma from individuals who have recovered from the disease, known as convalescent plasma (CP). CP therapy is a passive antibody therapy where the isolated plasma, containing antibodies from recovered patients, is administered to individuals with severe disease to suppress virulence and improve clinical symptoms. The blood plasma of recovered COVID-19 patients contains antibodies that can combat the infection. The FDA recommends CP Therapy as an investigational product during public health emergencies. Approximately 2,004 participating sites adhering to a single expanded access protocol by the US FDA had been registered, with around 7,774 patients enrolled, and 3,809 of them undergoing convalescent plasma transfusion. The experimental nature of convalescent plasma therapy continues to attract attention, with its potential effectiveness depending on sufficient supporting data.

Major companies are intensifying their focus on introducing innovative products to gain a competitive edge. One such innovation is the development of COVID-19 oral antiviral treatments. Antiviral treatments are designed to inhibit the replication and spread of viruses within the body. For example, in November 2021, Pfizer Inc., a US-based pharmaceutical company, launched PAXLOVID, a novel oral antiviral candidate for COVID-19. The Phase 2/3 EPIC-HR study assessing PAXLOVID's efficacy demonstrated a consistent safety profile, making it suitable for patients treated within three days of symptom onset. Interim analysis indicates that PAXLOVID has the potential to save lives, reduce the severity of COVID-19 infections, and prevent up to nine out of ten hospitalizations.

In October 2021, Sanofi and Regeneron Pharmaceuticals announced plans to commence clinical trials using the rheumatoid arthritis medication Kevzara (sarilumab) for managing COVID-19 symptoms. The US Food and Drug Administration (FDA) granted approval for Kevzara's use in treating rheumatoid arthritis. This drug is part of an ongoing collaborative effort between Sanofi and Regeneron focused on antibodies. Kevzara, a fully human monoclonal antibody, functions by obstructing the interleukin-6 (IL-6) pathway through binding and inhibiting the IL-6 receptor. IL-6 potentially contributes to the exacerbated inflammatory response observed in the lungs of severely or critically ill COVID-19 patients. Following a comprehensive evaluation by the Independent Data Monitoring Committee (IDMC) of available Phase 2 and Phase 3 data, adjustments to the trial will prioritize enrolling only critical patients to receive Kevzara at a dosage of 400 mg.

Major companies operating in the COVID-19 current therapy market report are Gilead Sciences, Inc., F. Hoffmann-La Roche AG, Ipca Laboratories Limited, Zydus Cadila, Regeneron Pharmaceuticals, Inc., Sun Pharmaceutical Industries Limited, AbbVie, Glenmark Pharmaceuticals Limited, Eli Lilly and Company, Wallace Pharmaceuticals, Inc., Mylab Discovery Solutions, Kalbe Farma, He Qi Group Foundation, Beijing Jinwofu Bioengineering Technology Company, Zhejiang Orient Gene Biotech Co. Ltd., Transasia Bio Medicals, Vanguard Diagnostics, HLL Lifecare Limited, Voxtur Bio Ltd., Biocryst Pharma, Clover Biopharmaceuticals, Inovio Pharmaceuticals, Inc., LAB-CARE Diagnostics, ImmunoScience, CPC Diagnostics, Sysmex Corporation, Atomo Diagnostics, Cellmid Limited, Moderna Therapeutics, Novavax, Bravovax, Ascletis Pharma, Altimmune, Hunan Lituo Biotechnology, Hangzhou Biotest Biotech, AmonMed Biotechnology, Getein Biotech, Beijing Tigsun Diagnostics, Vivacheck Lab, Seegene, SD Biosensor, Fujirebio, Siemens Healthcare Pte. Ltd., Senova, LetsGetChecked, Omega Diagnostics, Abingdon Health, Babylon, Motologic, F. Hoffmann-La Roche Ltd., Novacyt Group, AstraZeneca, Pfizer, Zentiva, Boehringer Ingelheim, GlaxoSmithKline, Merck & Co., Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi, Amgen and AdaptiveBiotechnologies, BioNtech, Cytodyn, Heat biologics, Johnson&Johnson, Takeda pharmaceuticals, Vaxart, Vir Biotechnology, Victory Square Health, Abbott Molecular Inc., ACRO Biotech, Advagen Biotech Ltd., BD, Boditech Med, Inc., Cellex Inc., CerTest Biotec, S.L., Hi Technologies, BATM, BioMedomics Quant Lease, CapeBio, Astel Diagnostics, Canary Health Technologies, Thermo Fisher Scientific

North America is the largest region in the COVID-19 current therapy market in 2023. Middle East is expected to be the fastest growing region in the global COVID-19 current therapy market share during the forecast period. The regions covered in the COVID-19 current therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the COVID-19 current therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The COVID-19 current therapy market includes revenues earned by entities by tocilizumab, favipiravir, and ivermectin. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

COVID-19 Current Therapy Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on covid-19 current therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for covid-19 current therapy? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The covid-19 current therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Drug Type: Antiviral; Monoclonal Antibodies; Corticosteroid; Supplements; Antimalarial; Interferons And Interleukin Inhibitors; Other Anti-Infective Drugs; Others
  • 1) By Route Of Administration: Oral; Intravenous
  • 2) By End-User: Hospitals; Clinics; Home Care; Others
  • Companies Mentioned: Gilead Sciences, Inc.; F. Hoffmann-La Roche AG; Ipca Laboratories Limited; Zydus Cadila; Regeneron Pharmaceuticals, Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. COVID-19 Current Therapy Market Characteristics

3. COVID-19 Current Therapy Market Trends And Strategies

4. COVID-19 Current Therapy Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global COVID-19 Current Therapy Market Size and Growth

  • 5.1. Global COVID-19 Current Therapy Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global COVID-19 Current Therapy Historic Market Size and Growth, 2020 - 2023, Value ($ Billion)
  • 5.3. Global COVID-19 Current Therapy Forecast Market Size and Growth, 2023 - 2024, 2025F, Value ($ Billion)

6. COVID-19 Current Therapy Market Segmentation

  • 6.1. Global COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Remdesivir
  • Hydroxychloroquine
  • Ritonavir
  • Lopinavir
  • Interferon Beta
  • Other Drug Type
  • 6.2. Global COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Oral
  • Intravenous
  • 6.3. Global COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • Hospitals
  • Clinics
  • Research Institutes
  • Other End Users

7. COVID-19 Current Therapy Market Regional And Country Analysis

  • 7.1. Global COVID-19 Current Therapy Market, Split By Region, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • 7.2. Global COVID-19 Current Therapy Market, Split By Country, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

8. Asia-Pacific COVID-19 Current Therapy Market

  • 8.1. Asia-Pacific COVID-19 Current Therapy Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • 8.3. Asia-Pacific COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • 8.4. Asia-Pacific COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

9. China COVID-19 Current Therapy Market

  • 9.1. China COVID-19 Current Therapy Market Overview
  • 9.2. China COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F,$ Billion
  • 9.3. China COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F,$ Billion
  • 9.4. China COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F,$ Billion

10. India COVID-19 Current Therapy Market

  • 10.1. India COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • 10.2. India COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • 10.3. India COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

11. Japan COVID-19 Current Therapy Market

  • 11.1. Japan COVID-19 Current Therapy Market Overview
  • 11.2. Japan COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • 11.3. Japan COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • 11.4. Japan COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

12. Australia COVID-19 Current Therapy Market

  • 12.1. Australia COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • 12.2. Australia COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • 12.3. Australia COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

13. Indonesia COVID-19 Current Therapy Market

  • 13.1. Indonesia COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • 13.2. Indonesia COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • 13.3. Indonesia COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

14. South Korea COVID-19 Current Therapy Market

  • 14.1. South Korea COVID-19 Current Therapy Market Overview
  • 14.2. South Korea COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • 14.3. South Korea COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • 14.4. South Korea COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

15. Western Europe COVID-19 Current Therapy Market

  • 15.1. Western Europe COVID-19 Current Therapy Market Overview
  • 15.2. Western Europe COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • 15.3. Western Europe COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • 15.4. Western Europe COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

16. UK COVID-19 Current Therapy Market

  • 16.1. UK COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • 16.2. UK COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • 16.3. UK COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

17. Germany COVID-19 Current Therapy Market

  • 17.1. Germany COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • 17.2. Germany COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • 17.3. Germany COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

18. France COVID-19 Current Therapy Market

  • 18.1. France COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • 18.2. France COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • 18.3. France COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

19. Italy COVID-19 Current Therapy Market

  • 19.1. Italy COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • 19.2. Italy COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • 19.3. Italy COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

20. Spain COVID-19 Current Therapy Market

  • 20.1. Spain COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • 20.2. Spain COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • 20.3. Spain COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

21. Eastern Europe COVID-19 Current Therapy Market

  • 21.1. Eastern Europe COVID-19 Current Therapy Market Overview
  • 21.2. Eastern Europe COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • 21.3. Eastern Europe COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • 21.4. Eastern Europe COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

22. Russia COVID-19 Current Therapy Market

  • 22.1. Russia COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • 22.2. Russia COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • 22.3. Russia COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

23. North America COVID-19 Current Therapy Market

  • 23.1. North America COVID-19 Current Therapy Market Overview
  • 23.2. North America COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • 23.3. North America COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • 23.4. North America COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

24. USA COVID-19 Current Therapy Market

  • 24.1. USA COVID-19 Current Therapy Market Overview
  • 24.2. USA COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • 24.3. USA COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • 24.4. USA COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

25. Canada COVID-19 Current Therapy Market

  • 25.1. Canada COVID-19 Current Therapy Market Overview
  • 25.2. Canada COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • 25.3. Canada COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • 25.4. Canada COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

26. South America COVID-19 Current Therapy Market

  • 26.1. South America COVID-19 Current Therapy Market Overview
  • 26.2. South America COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • 26.3. South America COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • 26.4. South America COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

27. Brazil COVID-19 Current Therapy Market

  • 27.1. Brazil COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • 27.2. Brazil COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • 27.3. Brazil COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

28. Middle East COVID-19 Current Therapy Market

  • 28.1. Middle East COVID-19 Current Therapy Market Overview
  • 28.2. Middle East COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • 28.3. Middle East COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • 28.4. Middle East COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

29. Africa COVID-19 Current Therapy Market

  • 29.1. Africa COVID-19 Current Therapy Market Overview
  • 29.2. Africa COVID-19 Current Therapy Market, Segmentation By Drug Type, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • 29.3. Africa COVID-19 Current Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion
  • 29.4. Africa COVID-19 Current Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2023, 2023-2024F, 2025F, $ Billion

30. COVID-19 Current Therapy Market Competitive Landscape And Company Profiles

  • 30.1. COVID-19 Current Therapy Market Competitive Landscape
  • 30.2. COVID-19 Current Therapy Market Company Profiles
    • 30.2.1. Gilead Sciences, Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. F. Hoffmann-La Roche AG
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Ipca Laboratories Limited
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Zydus Cadila
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Regeneron Pharmaceuticals, Inc.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. COVID-19 Current Therapy Market Other Major And Innovative Companies

  • 31.1. Sun Pharmaceutical Industries Limited
  • 31.2. AbbVie
  • 31.3. Glenmark Pharmaceuticals Limited
  • 31.4. Eli Lilly and Company
  • 31.5. Wallace Pharmaceuticals, Inc.
  • 31.6. Mylab Discovery Solutions
  • 31.7. Kalbe Farma
  • 31.8. He Qi Group Foundation
  • 31.9. Beijing Jinwofu Bioengineering Technology Company
  • 31.10. Zhejiang Orient Gene Biotech Co. Ltd
  • 31.11. Transasia Bio Medicals
  • 31.12. Vanguard Diagnostics
  • 31.13. HLL Lifecare Limited
  • 31.14. Voxtur Bio Ltd
  • 31.15. Biocryst Pharma

32. Global COVID-19 Current Therapy Market Competitive Benchmarking

33. Global COVID-19 Current Therapy Market Competitive Dashboard

34. Key Mergers And Acquisitions In The COVID-19 Current Therapy Market

35. COVID-19 Current Therapy Market Future Outlook and Potential Analysis

  • 35.1 COVID-19 Current Therapy Market In 2024 - Countries Offering Most New Opportunities
  • 35.2 COVID-19 Current Therapy Market In 2024 - Segments Offering Most New Opportunities
  • 35.3 COVID-19 Current Therapy Market In 2024 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer